Qing Li, MD PhD
@QingLi_MDPhD
Followers
113
Following
463
Statuses
129
Radiation Oncology Resident at UH Seidman Cancer Center, #Alumni Memorial Sloan Kettering Cancer Center, McGill University and Rutgers RWJ
Cleveland, OH
Joined April 2012
@lauren_henke @RadOncUH @angela_jia_ @KenGreggMP @kyle_carro63539 @Betyguevarasoto @MeiyingXing @ElthruEm @APrice_BeamOn @kris_lyons18 @KashaniRojano Best way to celebrate lunar new year is to get bubble tea together 🧧🧧🧧
0
0
2
RT @lauren_henke: Happy Lunar New Year from our @radoncuh residency teams to yours! 🧧🎉🎊 Boba courtesy of the fabulous @angela_jia_
https://…
0
3
0
0
0
0
RT @AriellaHanker: How does a tumor acquire all those resistance promoting alterations in the first place? Kudos to @AvanGupta @MSKCancerCe…
0
8
0
RT @to_be_elizabeth: 📌Does Postmastectomy Radiotherapy in 'Intermediate-Risk' Breast Cancer Impact Overall Survival? 👉🏻10-Year Results of…
0
43
0
RT @ErikaHamilton9: @Otto_DFCI presents #PATINA Maint ET + HP +/- Palbo in 1st line HER-2 maint 📌29.1 vs. 44.3 mo PFS with Palbo w/ 52…
0
8
0
RT @RohanPatelMD: UH RadOnc Medical and Physics residency annual holiday party at our amazing PD’s house! Not pictured is the complete mayh…
0
6
0
RT @ErikaHamilton9: @Icro_Meattini presents EUROPA - ET alone or XRT alone in women >70 in luminal early #bcsm XRT ☢️ affected QHS less t…
0
10
0
RT @MSKCancerCenter: #SABCS24: Join postdoctoral researcher Dr. @AvanGupta for her presentation on "APOBEC3 mutagenesis induces resistance-…
0
4
0
RT @RadOncTalks: Breast cancer management is heavily driven by molecular phenotype. Here are some classic phenotypes associated with breast…
0
1
0
RT @RohanPatelMD: Do you treat GU cancers? Have you had a patient that identifies as LGBTQIA2+? Have you felt scared of making a mistake? S…
0
2
0
RT @NiuSanford: We've had a lot of interest in GI-011 (LAP100) which is awesome. At the suggestion of @tedradonc, I prepped a short ppt to…
0
18
0
RT @AvanGupta: T-DXd has remarkable activity in HER2+ cancers but benefits vary even in HER2-high tumors. Our latest @CellRepMed study reve…
0
19
0
RT @PTarantinoMD: How do we build a new generation of safer and more active ADCs for treating cancer? 👉By understanding how they actually…
0
59
0
RT @PTarantinoMD: ADCs harbor 3 key elements: an antibody, a linker, a payload. Since the 1980s, ADCs mostly harbored microtubule and alky…
0
1
0
RT @KatsuakiMaehara: 1/2 🫁 Stage III - Unresectable NSCLC 🫁 🫁 Summary of treatment regimen as of October, 2024 🫁 🌟 @EORTC : Consensual d…
0
65
0